Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Murine cytomegalovirus infection of melanoma lesions delays tumor growth by recruiting and re-polarizing monocytic phagocytes in the tumor.

Wilski NA, Del Casale C, Purwin TJ, Aplin AE, Snyder CM.

J Virol. 2019 Aug 2. pii: JVI.00533-19. doi: 10.1128/JVI.00533-19. [Epub ahead of print]

PMID:
31375579
2.

In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE.

Mol Cancer Ther. 2019 Sep;18(9):1637-1648. doi: 10.1158/1535-7163.MCT-18-1056. Epub 2019 Jul 3.

PMID:
31270153
3.

C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo.

Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher SJ, Nguyen MQ, Aplin AE, Delmas V, Larue L.

Pigment Cell Melanoma Res. 2019 Jun 28. doi: 10.1111/pcmr.12807. [Epub ahead of print]

PMID:
31251472
4.

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.

Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY.

Nat Commun. 2019 Jun 25;10(1):2782. doi: 10.1038/s41467-019-10669-0.

5.

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE.

Pigment Cell Melanoma Res. 2019 Sep;32(5):687-696. doi: 10.1111/pcmr.12788. Epub 2019 May 20.

PMID:
31063649
6.

Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation.

Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES.

Nat Commun. 2019 Apr 11;10(1):1689. doi: 10.1038/s41467-019-09397-2.

7.

The plaque-aortic ring assay: a new method to study human atherosclerosis-induced angiogenesis.

Aplin AC, Nicosia RF.

Angiogenesis. 2019 Aug;22(3):421-431. doi: 10.1007/s10456-019-09667-z. Epub 2019 Apr 9.

PMID:
30968256
8.

CADM1 is a TWIST1-regulated suppressor of invasion and survival.

Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH 3rd, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE.

Cell Death Dis. 2019 Mar 25;10(4):281. doi: 10.1038/s41419-019-1515-3.

9.

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK.

Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18.

PMID:
30885979
10.

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade.

Nikbakht N, Tiago M, Erkes DA, Chervoneva I, Aplin AE.

J Invest Dermatol. 2019 Jul;139(7):1612-1615. doi: 10.1016/j.jid.2018.12.024. Epub 2019 Jan 28. No abstract available.

PMID:
30703359
11.

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE.

EMBO Mol Med. 2019 Feb;11(2). pii: e9081. doi: 10.15252/emmm.201809081.

12.

Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma.

Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner PB, Aplin AE, Aguirre-Ghiso J, Benovic JL.

Mol Cancer Res. 2019 Apr;17(4):963-973. doi: 10.1158/1541-7786.MCR-18-0574. Epub 2018 Dec 19.

PMID:
30567972
13.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
14.

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Vido MJ, Le K, Hartsough EJ, Aplin AE.

Cell Rep. 2018 Nov 6;25(6):1501-1510.e3. doi: 10.1016/j.celrep.2018.10.049.

15.

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.

Teh JLF, Aplin AE.

Clin Cancer Res. 2019 Feb 1;25(3):921-927. doi: 10.1158/1078-0432.CCR-18-1967. Epub 2018 Oct 4. Review.

PMID:
30287548
16.

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE.

Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16.

17.

Playing the Melanoma Endgame.

Teh JLF, Aplin AE.

Clin Cancer Res. 2018 Oct 1;24(19):4629-4630. doi: 10.1158/1078-0432.CCR-18-0989. Epub 2018 May 16.

PMID:
29769205
18.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 Aug;21(3):425-532. doi: 10.1007/s10456-018-9613-x. Review.

19.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

20.

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Apr 6;9(1):1404. doi: 10.1038/s41467-018-03710-1.

21.

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.

Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN.

Cancer Discov. 2018 May;8(5):556-567. doi: 10.1158/2159-8290.CD-17-0745. Epub 2018 Mar 1.

22.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Erratum in: Cancer Discov. 2018 Dec;8(12):1654.

23.

CKS1 expression in melanocytic nevi and melanoma.

Brożyna AA, Aplin A, Cohen C, Carlson G, Page AJ, Murphy M, Slominski AT, Carlson JA.

Oncotarget. 2017 Dec 23;9(3):4173-4187. doi: 10.18632/oncotarget.23648. eCollection 2018 Jan 9.

24.

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Jan 2;9(1):28. doi: 10.1038/s41467-017-02354-x. Erratum in: Nat Commun. 2018 Apr 6;9(1):1404.

25.

Novel therapeutic strategies and targets in advanced uveal melanoma.

Chua V, Aplin AE.

Curr Opin Oncol. 2018 Mar;30(2):134-141. doi: 10.1097/CCO.0000000000000425. Review.

PMID:
29206651
26.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

27.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE.

Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13.

28.

Running INTERFERONce on immunotherapy.

Rosenbaum S, Aplin A.

Pigment Cell Melanoma Res. 2018 May;31(3):352-353. doi: 10.1111/pcmr.12663. Epub 2017 Nov 21. No abstract available.

PMID:
29068157
29.

"If you want to go far, go together".

Aplin AE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):448. doi: 10.1111/pcmr.12619. No abstract available.

PMID:
28834183
30.

The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells.

Sample A, Zhao B, Wu C, Qian S, Shi X, Aplin A, He YY.

Photochem Photobiol. 2018 May;94(3):432-437. doi: 10.1111/php.12809. Epub 2017 Oct 8.

31.

Hyperactive FOXO1 results in lack of tip stalk identity and deficient microvascular regeneration during kidney injury.

Dang LTH, Aburatani T, Marsh GA, Johnson BG, Alimperti S, Yoon CJ, Huang A, Szak S, Nakagawa N, Gomez I, Ren S, Read SK, Sparages C, Aplin AC, Nicosia RF, Chen C, Ligresti G, Duffield JS.

Biomaterials. 2017 Oct;141:314-329. doi: 10.1016/j.biomaterials.2017.07.010. Epub 2017 Jul 7.

32.

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.

Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T.

J Transl Med. 2017 Jun 23;15(1):145. doi: 10.1186/s12967-017-1247-z.

33.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT.

Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.

34.

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE.

Mol Cancer Res. 2017 May;15(5):501-506. doi: 10.1158/1541-7786.MCR-17-0007. Epub 2017 Feb 21. Review.

35.

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE.

Mol Cancer Ther. 2017 Mar;16(3):516-528. doi: 10.1158/1535-7163.MCT-16-0552. Epub 2017 Jan 30.

36.

Numerical Simulation of Fracking in Shale Rocks: Current State and Future Approaches.

Hattori G, Trevelyan J, Augarde CE, Coombs WM, Aplin AC.

Arch Comput Methods Eng. 2017;24(2):281-317. doi: 10.1007/s11831-016-9169-0. Epub 2016 Jan 29.

37.

The Aortic Ring Assay and Its Use for the Study of Tumor Angiogenesis.

Aplin AC, Nicosia RF.

Methods Mol Biol. 2016;1464:63-72.

PMID:
27858356
38.

Triple jeopardy for people with albinism.

Arnheiter H, Long G, Aplin A, Harris J, Kelsh R.

Pigment Cell Melanoma Res. 2016 Sep;29(5):487. doi: 10.1111/pcmr.12517. No abstract available.

PMID:
27615283
39.

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.

Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE.

Cancer Res. 2016 Sep 15;76(18):5455-66. doi: 10.1158/0008-5472.CAN-15-3384. Epub 2016 Aug 3.

40.

The melanoma field with dendritic roots.

Aplin AE.

Pigment Cell Melanoma Res. 2016 Jul;29(4):397. doi: 10.1111/pcmr.12496. No abstract available.

PMID:
27320440
41.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

42.

Targeting mutant NRAS signaling pathways in melanoma.

Vu HL, Aplin AE.

Pharmacol Res. 2016 May;107:111-116. doi: 10.1016/j.phrs.2016.03.007. Epub 2016 Mar 15. Review.

43.

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE.

J Invest Dermatol. 2016 Feb;136(2):453-463. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.

44.

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.

Hartsough EJ, Aplin AE.

Clin Cancer Res. 2016 Apr 1;22(7):1550-2. doi: 10.1158/1078-0432.CCR-15-3054. Epub 2016 Feb 3.

45.

Hypoxia paradoxically inhibits the angiogenic response of isolated vessel explants while inducing overexpression of vascular endothelial growth factor.

Aplin AC, Nicosia RF.

Angiogenesis. 2016 Apr;19(2):133-46. doi: 10.1007/s10456-015-9493-2. Epub 2016 Jan 9.

PMID:
26748649
46.

Welcome to the New Year!

Arnheiter H, Long G, Aplin A, Harris J, Kelsh R.

Pigment Cell Melanoma Res. 2016 Jan;29(1):3. doi: 10.1111/pcmr.12446. No abstract available.

PMID:
26678867
47.

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T.

Am J Pathol. 2016 Jan;186(1):43-56. doi: 10.1016/j.ajpath.2015.09.011. Epub 2015 Nov 25.

48.

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.

Am J Pathol. 2015 Sep;185(9):2505-22. doi: 10.1016/j.ajpath.2015.04.026.

49.

The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.

Vido MJ, Aplin AE.

J Invest Dermatol. 2015 Oct;135(10):2355-2357. doi: 10.1038/jid.2015.239.

50.

Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.

Capparelli C, Rosenbaum S, Berger AC, Aplin AE.

J Biol Chem. 2015 Oct 2;290(40):24267-77. doi: 10.1074/jbc.M115.657270. Epub 2015 Aug 12.

Supplemental Content

Support Center